BOSTON--(BUSINESS WIRE)--Averion International Corp. (OTCBB:AVRO), a clinical research organization (CRO) specializing in oncology, medical devices, dermatology and nephrology, today announced a cost reduction initiative intended to increase its operating efficiencies and improve its competitive position. Averion’s new cost structure is expected to support its business growth strategy and assist the Company in improving profitability.
